Tryptamine Therapeutics (ASX:TYP) sets the table for psychedelic breakthrough in binge eating disorder

In the fast-evolving world of psychedelic medicine, one ASX-listed minnow is hoping to feast on a new frontier: Binge Eating Disorder (BED).

Tryptamine Therapeutics (ASX:TYP), a clinical-stage biopharma player, has inked a world-first trial agreement with Swinburne University to evaluate its proprietary IV-infused psilocin formulation, TRP-8803, in treating BED.

It’s a bold and tightly focused bet in a space where most drug developers cast a wide net.

BED affects an estimated 25-50% of obese individuals seeking treatment and has no approved therapies to date.

Tryp Therapeutics trial will dose 12 patients across two cohorts, with participants receiving two infusions of TRP-8803 two weeks apart, alongside psychotherapy.

The primary focus? Safety.

But it’s the exploratory endpoints—frequency of binge episodes and weight-related outcomes—that will likely stir investor and medical curiosity alike.

“Our CTRA to commence this world-first clinical patient trial for our lead drug treatment TRP-8803 marks an important step forward in Tryp’s clinical development pathway,”

said CEO Jason Carroll, citing the groundwork laid by strong safety data from Phase 1b studies.

Key Highlights:

• Open-label trial to be led by Professor Susan Rossell at Swinburne’s Centre for Mental Health

• Targets BED, the most prevalent eating disorder in the US and second in Australia

• TRP-8803 enables precise control of dosage and duration, unlike oral psilocybin

• Phase 2a data from University of Florida using oral TRP-8802 showed >80% reduction in binge episodes

While Tryp is not the only psychedelic player on the ASX, its niche focus and IV delivery method set it apart. TRP-8803’s touted ability to control the depth and duration of the psychedelic state—and critically, to stop treatment mid-course if necessary—gives it an edge on the safety front.

The partnership with Swinburne provides more than academic backing—it adds real-world credibility to a space still viewed warily by regulators and the public alike.

Critically, Tryp is playing the long game.

With plans for further trials targeting fibromyalgia and IBS also in the pipeline, the company is laying the foundation for a diversified, neuroscience-driven portfolio.

But first, it must prove TRP-8803 can safely—and effectively—break the cycle of bingeing in a cohort where current therapies fall short.

For a company trading in the low microcap range, the stakes are high. But then again, so is the potential payoff if TRP-8803 lives up to its billing as a more precise, scalable, and commercially viable version of psychedelic therapy.

One dose at a time.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.